Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

NCT06900595 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

NIH

Sponsor class

Conditions

Locally Advanced Adrenal Cortical Carcinoma
Metastatic Adrenal Cortical Carcinoma
Recurrent Adrenal Cortical Carcinoma
Stage III Adrenal Cortical Carcinoma AJCC v8
Stage IV Adrenal Cortical Carcinoma AJCC v8
Unresectable Adrenal Cortical Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib
BIOLOGICAL: Cemiplimab
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

National Cancer Institute (NCI)